Xtant Medical Holdings XTNT R&D credit carryforward
R&D credit carryforward at other companies
Other financials
Where this comes from
Reported directly by Xtant Medical Holdings in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch.
The official record: Xtant Medical Holdings’s 10-K, filed March 31, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xtant Medical Holdings's r&d credit carryforward.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xtant Medical Holdings's r&d credit carryforward?
- Xtant Medical Holdings (XTNT) reported r&d credit carryforward of $850K in Q4 2024.
- What is the long-term trend for Xtant Medical Holdings's r&d credit carryforward?
- Over 2 years (2022 to 2024), Xtant Medical Holdings's r&d credit carryforward has grown at a 72.1% compound annual growth rate (CAGR), from $287K to $850K.
- What does r&d credit carryforward mean?
- This represents the value of research and development tax credits that have been earned but not yet utilized to offset tax liabilities, which can be carried forward to future tax years. It serves as a valuable asset that can reduce future cash tax outflows, directly benefiting the company's bottom line. Investors view this as a potential source of liquidity and a reflection of the company's historical investment in innovation.